Smith & Nephew (NYSE:SNN – Get Rating) and Ortho Regenerative Technologies (OTCMKTS:ORTIF – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.
This table compares Smith & Nephew and Ortho Regenerative Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Smith & Nephew||N/A||N/A||N/A|
|Ortho Regenerative Technologies||N/A||N/A||-269.68%|
Valuation and Earnings
This table compares Smith & Nephew and Ortho Regenerative Technologies’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Smith & Nephew||$5.21 billion||2.19||$524.00 million||N/A||N/A|
|Ortho Regenerative Technologies||N/A||N/A||-$3.93 million||($0.11)||-1.78|
This is a summary of recent ratings and recommmendations for Smith & Nephew and Ortho Regenerative Technologies, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Smith & Nephew||0||4||1||0||2.20|
|Ortho Regenerative Technologies||0||0||1||0||3.00|
Ortho Regenerative Technologies has a consensus target price of $1.35, indicating a potential upside of 588.25%. Given Ortho Regenerative Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Ortho Regenerative Technologies is more favorable than Smith & Nephew.
Volatility & Risk
Smith & Nephew has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Ortho Regenerative Technologies has a beta of -1.16, suggesting that its share price is 216% less volatile than the S&P 500.
Insider & Institutional Ownership
8.6% of Smith & Nephew shares are held by institutional investors. 1.0% of Smith & Nephew shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Smith & Nephew beats Ortho Regenerative Technologies on 6 of the 8 factors compared between the two stocks.
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
About Ortho Regenerative Technologies
Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.